B-cell-depleting therapy in systemic lupus erythematosus

American Journal of Medicine

Volumn 125, Issue 4, 2012, Pages 327-336

  Ramos Casals, Manuel ^a   Sanz, Iñaki ^b   Bosch, Xavier ^c   Stone, John H ^d   Khamashta, Munther A ^e  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c HOSPITAL CLÍNIC   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Belimumab; Epratuzumab; Ocrelizumab; Rituximab; Systemic lupus erythematosus

Indexed keywords

AMG 623; ATACICEPT; AZATHIOPRINE; BELIMUMAB; EPRATUZUMAB; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CELL SELECTION; CELL SURVIVAL; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ETHNICITY; FOLLOW UP; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84858986751     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.09.010     Document Type: Review

References (50)

1. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587-596. (Pubitemid 46241445)
2. Mitka M. Treatment for lupus, first in 50 years, offers modest benefits, hope to patients. JAMA. 2011;305:1754-1755.
3. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6:326-337.
4. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2010;62:201-210.
5. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168-1178.
6. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62: 222-233.
7. Furie R, Looney J, Rovin B, et al. Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase iii lunar study. Ann Rheum Dis. 2010; 69(Suppl 3):549.
8. Furie R, Rovin BH, Appel G, et al. Effect of rituximab on anti-doublestranded DNA antibody and C3 levels and relationship to response: results from the LUNAR trial. Ann Rheum Dis. 2010;69(Suppl 3):550.
9. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III BELONG study. Arthritis Rheum. 2010;62 (Suppl): S606-S607.
10. Wallace DJ, Hobbs K, Houssiau F, et al. Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients. Ann Rheum Dis. 2008;67(Suppl II):212.
11. Petri MA, Hobbs K, Gordon C, et al. Randomized controlled trials of epratuzumab (anti-CD-22MAB targeting B cells) reveal clinically meaningful improvements in patients with moderate and severe SLE flares. Ann Rheum Dis. 2008;67(Suppl II):53.
12. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum. 2010;62(Suppl):S605.
13. Petri M, Furie R, Merrill J, et al. Six-year experience with belimumab in patients with SLE. Ann Rheum Dis. 2011 (Abstract THU0409).
14. Navarra SV, Guzmán RM, Gallacher AE, et al; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721-731.
15. Vollenhoven RF, Schwarting A, Navarra S, et al; BLISS-52 and BLISS-76 Study Groups. Durability of response in SLE patients treated with belimumab in the phase 3 BLISS-52 and BLISS-76 studies. Ann Rheum Dis. 2011 (Abstract THU0431).
16. D'Cruz D, Manzi S, Sánchez-Guerrero J, et al; BLISS-52 and BLISS-76 Study Groups. Belimumab reduced disease activity across multiple organ domains in patients with SLE: combined results from BLISS-52 and BLISS-76. Ann Rheum Dis. 2011 (Abstract THU0421).
17. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011;10:335-336.
18. Gunnarsson I, van Vollenhoven RF. Biologicals for the treatment of systemic lupus erythematosus? Ann Med. 2011 Apr 15 [Epub ahead of print].
19. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-776.
20. Vital EM, Dass S, Buch MH, et al. Rituximab responses in systemic lupus erythematosus explained by B cell biomarkers. Arthritis Rheum. 2011 May 25. doi: 10.1002/art.30466 [Epub ahead of print].
21. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:R75.
22. Tesfa1 D, Ajeganova S, Hägglund1 H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B-lymphocyte depletion and infections. Arthritis Rheum. 2011 May 10. doi: 10.1002/art.30427 [Epub ahead of print].
23. Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford). 2011 Mar 12 [Epub ahead of print].
24. Galarza-Maldonado C, Kourilovitch MR, Molineros JE, et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun Rev. 2010;10:108-111.
25. Ramos-Casals M, García-Hernández FJ, de Ramón E, et al BIOGEAS Study Group. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010; 28:468-476.
26. Terrier B, Amoura Z, Ravaud P, et al Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458-2466.
27. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Longterm efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25: 3586-3592.
28. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti- CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010;19: 213-219.
29. Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 2009;4:579-587.
30. Favas C, Isenberg DA. B-cell-depletion therapy in SLE-what are the current prospects for its acceptance? Nat Rev Rheumatol. 2009;5:711- 716.
31. Sanz I. The conundrum of B cell depletion in SLE. Nat Rev Rheumatol. 2009;5:304-305.
32. Bruce IN. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22:273-277.
33. Rivera TL, Belmont HM, Malani S, et al. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol. 2009; 36:298-305.
34. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49:128-140.
35. Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol. 2011;40:159-169.
36. Merrill JT, Wallace DJ, Furie RA, et al. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). Arthritis Rheum. 2010;62(Suppl):S608.
37. van Vollenhoven RF, Jacobsen S, Wallace D, et al; SLICC/IRBIS group. Biologics use in SLE in 18 centers-data from the international registry for biologics in SLE (IRBIS). Ann Rheum Dis. 2011 (Abstract THU0432).
38. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22:504-509.
39. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008;67:1011-1016. (Pubitemid 351956665)
40. Croca SC, Isenberg DA. Analysis of the use of rituximab in the treatment of lupus nephritis. Arthritis Rheum. 2010;62(Suppl):S479.
41. Croca SC, Isenberg DA. Immunoglobulin levels as potential predictors of response to B-cell depletion. Arthritis Rheum. 2010;62(Suppl): S195.
42. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48: 455-459. (Pubitemid 36278014)
43. Jónsdóttir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330-334. (Pubitemid 351281266)
44. Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008;126:282-290.
45. Conti F, Ceccarelli F, Perricone C, et al. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1148-1152.
46. Díaz-Lagares C, Pérez-Alvarez R, García- Hernández FJ, et al BIOGEAS Study Group. Rates of and risk factors for severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther. 2011;13:R112.
47. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with biologic and synthetic DMARD therapy in rheumatic diseases: an analysis of the FDA adverse event reporting system database. Arthritis Rheum. 2010;62(Suppl):S292.
48. Furie R, Zamani O, Wallace D, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through Wk 76. Arthritis Rheum. 2010;62(Suppl):S606.
49. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066-1073.
50. Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev. 2011;63:127-156.